Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
Sonali M. Smith, Brandelyn N. Pitcher, Sin Ho Jung, Nancy L. Bartlett, Nina Wagner-Johnston, Steven I. Park, Kristy L. Richards, Amanda F. Cashen, Anthony Jaslowski, Scott E. Smith, Bruce D. Cheson, Eric Hsi, John P. Leonard
Dive into the research topics of 'Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials'. Together they form a unique fingerprint.